We narrowed to 9,269 results for: ef1

#87306-AAV5

Ready-to-use AAV5 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

Li Zhang

Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

July 22, 2020

Academic Institutions and Nonprofits only

#169128-AAV1

Ready-to-use AAV1 particles produced from pAAV-DIO-EF1α-mKate2-PDE4D3-Cat (#169128). In addition to the viral particles, you will also receive purified pAAV-DIO-EF1α-mKate2-PDE4D3-Cat plasmid DNA. EF1a-driven, Cre-dependent expression of truncated PDE4D3 and mKate2. These AAV preparations are suitable purity for injection into animals.

Georg Nagel

Zhang et al Nature. 2021 Sep;597(7875):245-249. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#137162-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-EYFP (#137162). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-EYFP plasmid DNA. EF1a-driven expression of EYFP in the presence of Cre (inhibited in the presence of Flp). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Feb. 2, 2021

Academic Institutions and Nonprofits only

#137120-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-GCaMP6M (#137120). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-GCaMP6M plasmid DNA. EF1a-driven expression of GCaMP6m in the presence of Cre recombinase (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 23, 2020

Academic Institutions and Nonprofits only

#137123-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-GCaMP6F (#137123). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-GCaMP6F plasmid DNA. EF1a-driven, Cre-dependent expression of GCaMP6f (inhibited in presence of Flp). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 5, 2021

Academic Institutions and Nonprofits only

#203842-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-fDIO-eGFP-2A-Cre-WPRE (#203842). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-eGFP-2A-Cre-WPRE plasmid DNA. Flp-dependent Cre and EGFP expression under the EF1a promoter. These AAV preparations are suitable purity for injection into animals.

Ivo Spiegel

Roethler et al Neuron. 2023 Jun 20:S0896-6273(23)00399-

Nov. 13, 2025

Academic Institutions and Nonprofits only

#137137-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-oScarlet (#137137). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-oScarlet plasmid DNA. EF1a-driven, Cre-dependent expression of oScarlet (inhibited in presence of Flp). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 8, 2021

Academic Institutions and Nonprofits only

#87306-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Li Zhang

Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

July 22, 2020

Academic Institutions and Nonprofits only

#26966-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

March 27, 2024

Academic Institutions and Nonprofits only

#55639-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-fDIO hChR2(H134R)-EYFP (#55639). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO hChR2(H134R)-EYFP plasmid DNA. Ef1a-driven, Flp-dependent expression of ChR2(H134R)-EYFP. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Feb. 7, 2025

Academic Institutions and Nonprofits only

#35509-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO hChR2(E123T/T159C)-EYFP (#35509). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO hChR2(E123T/T159C)-EYFP plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin E123T/T159C mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

Feb. 21, 2018

Academic Institutions and Nonprofits only

#35509-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO hChR2(E123T/T159C)-EYFP (#35509). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO hChR2(E123T/T159C)-EYFP plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin E123T/T159C mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

Feb. 21, 2018

Academic Institutions and Nonprofits only

#51082-AAV1

Ready-to-use AAV1 particles produced from AAV-EF1a-DIO-GCaMP6s-P2A-nls-dTomato (#51082). In addition to the viral particles, you will also receive purified AAV-EF1a-DIO-GCaMP6s-P2A-nls-dTomato plasmid DNA. GCaMP6s calcium sensor and bicistronic, physically separate nuclear localized dTomato expression under the EF1a promoter. These AAV preparations are suitable purity for injection into animals.

Jonathan Ting

Sept. 19, 2017

Academic Institutions and Nonprofits only

#112677-AAV8

Ready-to-use AAV8 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Sept. 8, 2020

Academic Institutions and Nonprofits only

#112677-AAV5

Ready-to-use AAV5 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Aug. 26, 2019

Academic Institutions and Nonprofits only

#20299-AAV9

Ready-to-use AAV9 particles produced from pAAV-EF1a-double floxed-mCherry-WPRE-HGHpA (#20299). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-mCherry-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent mCherry expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 22, 2025

Academic Institutions and Nonprofits only

#112677-AAV9

Ready-to-use AAV9 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Sept. 8, 2020

Academic Institutions and Nonprofits only

#112677-AAV1

Ready-to-use AAV1 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Dec. 2, 2019

Academic Institutions and Nonprofits only

#112677-AAV2

Ready-to-use AAV2 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Jan. 17, 2020

Academic Institutions and Nonprofits only

#51083-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV-EF1a-DIO-GCaMP6f-P2A-nls-dTomato (#51083). In addition to the viral particles, you will also receive purified AAV-EF1a-DIO-GCaMP6f-P2A-nls-dTomato plasmid DNA. Cre-dependent GCaMP6f calcium sensor and physically separate nuclear tdTomato, under control of the EF1a promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Jonathan Ting

June 7, 2017

Academic Institutions and Nonprofits only

#112677-AAVrg

Ready-to-use AAV Retrograde particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

July 16, 2019

Academic Institutions and Nonprofits only

#124603-AAV9

Ready-to-use AAV9 particles produced from pAAV-EF1a-DIO-ChrimsonR-mRuby2-KV2.1-WPRE-SV40 (#124603). In addition to the viral particles, you will also receive purified pAAV-EF1a-DIO-ChrimsonR-mRuby2-KV2.1-WPRE-SV40 plasmid DNA. EF1a-driven, Cre-dependent expression of ChrimsonR fused to mRuby2 fluorophore and targeted to neuronal soma for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Christopher Harvey

Chettih et al Nature. 2019 Mar 6. pii: 10.1038/s41586-

Sept. 26, 2019

Academic Institutions and Nonprofits only

#20298-AAV5

Ready-to-use AAV5 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 15, 2018

Academic Institutions and Nonprofits only

#20298-AAV9

Ready-to-use AAV9 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

March 30, 2018

Academic Institutions and Nonprofits only

#20298-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Oct. 12, 2017

Academic Institutions and Nonprofits only

#20297-AAV9

Ready-to-use AAV9 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

March 15, 2018

Academic Institutions and Nonprofits only

#20297-AAV5

Ready-to-use AAV5 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 15, 2018

Academic Institutions and Nonprofits only

#20297-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 15, 2018

Academic Institutions and Nonprofits only

#20297-AAV8

Ready-to-use AAV8 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Dec. 18, 2017

Academic Institutions and Nonprofits only

#20298-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Oct. 12, 2017

Academic Institutions and Nonprofits only

#20297-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Aug. 22, 2017

Academic Institutions and Nonprofits only

#20298-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 8, 2020

Academic Institutions and Nonprofits only